Application of Maastricht 2-2000 Guidelines for the Management of Helicobacter pylori among Specialists and Primary Care Physicians in Israel: Are We Missing the Malignant Potential of Helicobacter pylori?

Journal of Clinical Gastroenterology

Volumn 38, Issue 4, 2004, Pages 322-325

  Shirin, Haim ^a,d   Birkenfeld, Shlomo ^b   Shevah, Orit ^a   Levine, Arie ^a   Epstein, Julia ^a   Boaz, Mona ^a,d   Niv, Yaron ^c,d   Avni, Yona ^a,d  

^a WOLFSON MEDICAL CENTER   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Gastric cancer; Helicobacter pylori; Maastricht 2 2000 Consensus Report

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; ISRAEL; MEDICAL SOCIETY; MEDICAL SPECIALIST; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; ISRAEL; OMEPRAZOLE; PHYSICIANS; PRACTICE GUIDELINES; PRIMARY HEALTH CARE; QUESTIONNAIRES;

EID: 1642392148     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200404000-00005     Document Type: Review

References (16)

1. The EUROGAST Study Group. Epidemiology and risk factors for H. pylori infection among 3194 asymptomatic subjects in 17 populations. Gut. 1993;34:1672-1676.
2. The EUROGAST Study Group. An international association between H. pylori infection and gastric cancer. Lancet. 1993;341:1359-1365.
3. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994;330:1267-1271.
4. Donohoe MT. Comparing generalist and speciality care: discrepancies, deficiencies, and excesses. Arch Intern Med. 1998;158:1596-1608.
5. Breuer T, Sudhop T, Goodman KJ, et al. How do practicing clinicians manage Helicobacter pylori-related gastrointestinal diseases in Germany? A survey of gastroenterologists and family practitioners. Helicobacter. 1998;3:1-8.
6. Breuer T, Goodman KJ, Malaty HM, et al. How do clinicians practicing in the U.S. manage Helicobacter pylori-related gastrointestinal diseases? A comparison of primary care and specialist physicians. Am J Gastroenterol. 1998;93:553-561.
7. Hirth RA, Fendrick AM, Chernew ME. Specialist and generalist physicians' adoption of antibiotic therapy to eradicate Helicobacter pylori infection. Med Care. 1996;34:1194-1204.
8. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167-180.
9. International Agency for Research on Cancer. Shistosomes, Liver Flukes and Helicobacter Pylori. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC: Lyon, France; 1994:61.
10. Chan FKL, To KF, Justin CY, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomized trial. Lancet. 2002;359: 9-13.
11. Lanas A, Fuentes J, Benito R, et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2002;16:779-786.
12. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344:967-973.
13. Huang J, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease: a meta-analysis. Lancet. 2002;359:14-22.
14. O'Connor HJ. Helicobacter pylori and dyspepsia: physicians' attitudes, clinical practice, and prescribing habits. Aliment Pharmacol Ther. 2002; 16:487-496.
15. Perri F, Ricciardi R, Merla A, et al. Appropriateness of urea breath test: a prospective observational study based on Maastricht 2000 guidelines. Aliment Pharmacol Ther. 2002;16:1443-1447.
16. Houben MH, van de Beek D, Hensen EF, et al. A systemic review of Helicobacter pylori eradication therapy-the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther. 1999;13:1047-1055.